cinobufotalin has been researched along with Adenocarcinoma of Lung in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, WF; Deng, ST; Deng, YL; Fang, WY; Hou, RT; Hu, Z; Li, YH; Liu, JH; Liu, X; Liu, Z; Su, Y; Wang, YB; Wu, LY; Xian, RT; Xie, YY; Xu, P; Yan, WW; Yang, HL; Zhu, ZB | 1 |
1 other study(ies) available for cinobufotalin and Adenocarcinoma of Lung
| Article | Year |
|---|---|
The small molecule chemical compound cinobufotalin attenuates resistance to DDP by inducing ENKUR expression to suppress MYH9-mediated c-Myc deubiquitination in lung adenocarcinoma.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma of Lung; Antineoplastic Agents; beta Catenin; Bufanolides; Calmodulin-Binding Proteins; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Myosin Heavy Chains; Myosins; Nasopharyngeal Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Transcription Factors; Ubiquitin-Specific Peptidase 7 | 2022 |